Thanks for posting this LTG - this positions TRXC very well in the entire market segment. Q1 2016 will be very exciting and those are some incentivized milestone payments to move along commercialization.
This is great news for Titan. Obviously no way that Warren Robotics will be looking at Alf/Transenterix which means one of two things: either Warren Robotics is developing their own (hard to believe that if JJDC owns 24.6% of Warren Robotics) or they will acquire a surgical robotics platform on their own.
IMO, this only enhances the possibility that Warren Robotics will take a serious look at Titan Medical ($TITXF).